Short-term treatment duration for HCV-2 and HCV-3 infected patients
- 1 October 2006
- journal article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 38 (10) , 741-748
- https://doi.org/10.1016/j.dld.2006.06.006
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3New England Journal of Medicine, 2005
- Tinkering and Tailoring With Hcv Therapy: Can We Get Away With Less?Hepatology, 2004
- Treatment With Pegylated Interferon and Ribavarin in Hcv Infection With Genotype 2 Or 3 for 14 Weeks: A Pilot StudyHepatology, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2aGastroenterology, 2001
- Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C VirusThe Journal of Infectious Diseases, 2000
- Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α TherapyScience, 1998
- Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis CGastroenterology, 1997
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981